Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    Psychedelic therapy: what the evidence on MDMA and psilocybin shows

    In August 2024 the developer, Lykos, said the FDA had declined to approve MDMA-assisted therapy for PTSD and asked for another phase 3 trial, after its advisory committee voted that the data did not show the drug was effective.[1][2] Synthetic psilocybin (COMP360) for treatment-resistant depression is further along: its developer reports two positive phase 3 trials and announced on 9 November 2026 that it had completed its FDA application.[3][4] Neither MDMA nor psilocybin is FDA-approved for PTSD or depression, while Oregon and Colorado run state-regulated psilocybin programmes outside the FDA system.[1][5][6][7]

    Editor reviewedStrict sourcingUpdated Analysis38 claims · 100% primaryMental health, Health and medicine, Tech policy
    Show:

    If you are struggling or thinking about suicide, help is available now. In the US, call or text 988 or chat at 988lifeline.org.[8] In the UK and Ireland, call Samaritans free on 116 123.[9] Elsewhere, find a local helpline at findahelpline.com.[10]

    This analysis is not medical or legal advice, and it is not a recommendation to use any psychedelic. Do not start, stop or change a treatment without a clinician, and do not use unregulated substances on the basis of this page. Opinions appear only in the interpretation and forecast blocks.

    Psychedelic-assisted therapy pairs a psychedelic drug with structured psychological support, and two programmes have gone furthest through the FDA process: MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression.[11][4] Their paths have split. This page sets out what the trials found, why regulators and researchers disagree about them, and how state programmes work, as of 14 November 2026. Background on the conditions is in PTSD explained and depression explained.

    MDMA for PTSD: the 2024 FDA decision

    On 4 June 2024 the FDA’s Psychopharmacologic Drugs Advisory Committee reviewed Lykos Therapeutics’ application for midomafetamine (MDMA) capsules for PTSD.[11] It voted 9 to 2 that the data did not show the drug was effective; many members said functional unblinding and unmanaged expectation and selection bias limited the efficacy analyses.[2] Members who voted yes shared those concerns but said they could not overlook the large effect sizes.[12] The committee voted 10 to 1 that the benefits, with FDA’s proposed risk-management programme, did not outweigh the risks, and many members asked for more efficacy and safety data.[13]

    On 9 August 2024 Lykos announced that the FDA had issued a complete response letter and requested an additional phase 3 study, with issues echoing the advisory meeting.[1] Lykos said the concerns included durability of effect and expectancy bias stemming mainly from participants with prior MDMA use; it maintained that its data were sufficient.[14] The company said panelists also questioned how much the psychotherapy component contributes, and its chief executive said another phase 3 trial would take several years.[15][16]

    What the MDMA trials found

    The first phase 3 trial (MAPP1, published in 2021) was randomised, double-blind and placebo-controlled in people with severe PTSD; it reported that MDMA-assisted therapy reduced CAPS-5 symptom scores significantly more than placebo with the same therapy, with an effect size of 0.91.[17] The confirmatory trial (MAPP2, 2023) randomised 104 people with moderate to severe PTSD; scores fell by 23.7 points with MDMA versus 14.8 with placebo and therapy (effect size 0.7).[18] In MAPP2, five people on MDMA and two on placebo had a severe adverse event, and there were no deaths or serious adverse events.[19]

    In August 2024 the journal Psychopharmacology retracted a 2020 pooled analysis of long-term outcomes from six phase 2 MDMA trials. It cited protocol violations amounting to unethical conduct at one study site that the authors knew of but did not disclose, and an incompletely declared competing interest; several authors disagreed with the retraction.[20]

    The disagreement is less about whether scores fell than about what caused the fall. MDMA’s effects are hard to mask, so a placebo group may know it got placebo, and advisers judged that this, plus participant selection, made the size of the drug effect hard to interpret.[2] Supporters point to large, consistent effects across two trials.[12][18] In our assessment, that makes the evidence moderate rather than strong: it comes from randomised trials, but from trials whose blinding FDA advisers did not accept.

    Psilocybin for depression

    A peer-reviewed phase 2 trial published in 2022, in 233 adults with treatment-resistant depression and funded by the developer, found that a single 25 mg dose of synthetic psilocybin reduced depression scores more than a 1 mg control at three weeks,[21] but sustained response at 12 weeks was not generally supported, and adverse events affected 77% of participants.[22][23] Compass Pathways reports that COMP360 met its goals in two phase 3 trials in treatment-resistant depression involving more than 1,000 participants.[3] In its 3 November 2026 results, the company reported 52-week open-label data from COMP005 and 6-month data from COMP006, and said an extra dose extended benefit to a year; these are company-reported figures.[24]

    The FDA granted Compass a Commissioner’s National Priority Voucher, which can shorten review to one to two months after filing, and COMP360 holds Breakthrough Therapy designation.[25] On 3 November 2026 Compass said its rolling application was nearing completion and that it planned to file the final submission within two weeks.[26] On 9 November it announced that the submission was complete.[4] The company also said a late-stage PTSD trial is under way and it is working with the US Department of Veterans Affairs on a trial in veterans.[27] Executive Order 14401 of April 2026 directs priority vouchers to eligible psychedelic drugs and asks for a prompt rescheduling review after phase 3 success, but it did not change their legal status.[28][29][30]

    Compass’s own forecast is a US launch in the first half of 2027, subject to FDA approval.[31] Our reading: the final filing was completed on 9 November 2026, so if the voucher’s one-to-two-month review applies, an FDA decision could come in early 2027, but approval is not assured.[4][25] Psilocybin is still a federal Schedule I substance, and the executive order asks only for a rescheduling review after phase 3 success.[32][29] Independent experts call the evidence promising but limited, and the MDMA case shows that FDA advisers can reject a programme with positive phase 3 results.[33][2]

    State programmes: Oregon and Colorado

    Oregon’s Measure 109, passed in November 2020, directs the Oregon Health Authority to license and regulate psilocybin products and services.[6] Services consist of preparation, administration and integration sessions with a licensed facilitator.[34] They are open to adults 21 and older, including non-residents, without a prescription or medical referral, and products can be bought only at a licensed service center during an administration session.[35][36] The state calls the services a health and wellness option and notes psilocybin remains a federal Schedule I substance.[32] On 1 September 2026 the programme merged into a combined Medical Cannabis & Psilocybin Section.[37]

    Colorado’s Department of Revenue says the state became the second, after Oregon, to legalise psilocybin mushrooms for personal use or use by healing centers, under a law signed in May 2023.[7] Its Natural Medicine Division licenses healing centers, cultivators, manufacturers and testing facilities, while the Department of Regulatory Agencies regulates facilitators.[38][7]

    State programmes are not FDA-approved treatment. Oregon requires no diagnosis or prescription and frames its services as wellness, so outcomes there say little about efficacy for a specific condition.[35][32] The FDA route and the state route are answering different questions: whether a defined product treats a defined disorder, versus whether adults may access supervised use.

    Where the evidence stands

    Across both drugs, the strongest evidence is randomised trials, but each has a caveat. For MDMA, FDA advisers did not accept that blinding held, and a pooled analysis of earlier phase 2 trials was retracted.[2][20] For psilocybin, the peer-reviewed phase 2 result was short-lived and side effects were common, and phase 3 detail so far comes from the developer.[22][3] Penn’s Leonard Davis Institute experts sum up the field as promising but limited, needing larger and more rigorous trials.[33] See also our analysis of new depression treatments.

    Competing views

    Large effects justify faster access

    Supporters point out that two phase 3 MDMA trials reported large symptom reductions in PTSD, and the psilocybin developer reports positive phase 3 results lasting months. A 2026 executive order backs faster review and a rescheduling review after phase 3 success.[17][18][3][28][29]

    Trial design undermines the results

    FDA advisers said participants could often tell whether they had the drug, so expectation and selection bias cloud the efficacy data. A journal retracted a pooled MDMA analysis over undisclosed protocol violations.[2][13][20]

    Promising but not yet proven

    Independent experts call the evidence promising but limited and want larger, longer trials. Phase 3 psilocybin figures so far are the developer's own summaries.[33][23][24]

    Next in the crash course

    Questions readers ask

    Is MDMA therapy approved for PTSD?

    No. In August 2024 the FDA issued a complete response letter for Lykos Therapeutics' MDMA application and asked for an additional phase 3 study, according to the company.[1]

    Why did FDA advisers vote against MDMA therapy?

    The committee voted 9 to 2 that the data did not show effectiveness and 10 to 1 that benefits did not outweigh risks. Many members cited functional unblinding, unmanaged expectation and selection bias, and a need for more efficacy and safety data.[2][13]

    Is psilocybin approved for depression?

    Not as of mid-November 2026. Compass Pathways, which still describes COMP360 as investigational, announced on 9 November 2026 that it had completed its New Drug Application, and it expects a launch in the first half of 2027 if the FDA approves it.[5][4][31]

    Can I legally get psilocybin in Oregon?

    Oregon licenses psilocybin services for adults 21 and older, with no prescription needed, delivered by licensed facilitators at licensed service centers after a preparation session. Psilocybin remains a Schedule I drug under federal law.[35][34][32]

    How does Colorado's programme differ?

    Colorado legalised psilocybin mushrooms for personal use and use by licensed healing centers under a 2023 law, with the Department of Revenue licensing businesses and the Department of Regulatory Agencies regulating facilitators.[7][38]

    Sources

    · 38 claims from 17 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      On 9 August 2024 Lykos Therapeutics announced that the FDA had issued a complete response letter for its MDMA application and requested an additional phase 3 study, saying the issues echoed those raised at the advisory committee. confirmedas of 2024-08-09

    2. [2]

      The advisory committee voted 9 to 2 that the available data did not show MDMA was effective in PTSD; many members said functional unblinding and unmanaged expectation and selection bias limited the efficacy analyses. confirmedas of 2024-06-04

    3. [3]

      Compass Pathways reports that its synthetic psilocybin COMP360 met its goals in two phase 3 trials in treatment-resistant depression (COMP005 and COMP006) involving more than 1,000 participants. reportedas of 2026-08-05

    4. [4]

      On 9 November 2026 Compass Pathways announced that it had completed its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression. confirmedas of 2026-11-09

    5. [5]

      As of 9 November 2026, Compass described COMP360 as an investigational synthetic psilocybin formulation, meaning it was not FDA-approved. confirmedas of 2026-11-09

    6. [6]

      Oregon's Measure 109, passed in November 2020 and codified as ORS 475A, directs the Oregon Health Authority to license and regulate psilocybin products and psilocybin services. confirmedas of 2026-11-07

    7. [7]

      Colorado's Department of Revenue says Colorado became the second state after Oregon to legalise psilocybin mushrooms for personal use or use by healing centers when SB23-290 was signed in May 2023, with the Department of Revenue licensing businesses and the Department of Regulatory Agencies regulating facilitators. confirmedas of 2026-11-07

    8. [8]

      The 988 Suicide & Crisis Lifeline provides free, confidential emotional support by call, text or chat to people in suicidal crisis or emotional distress 24 hours a day across the US and its territories, through a network of over 200 local crisis centers. confirmedas of 2026-10-11

    9. [9]

      In the UK and Ireland, Samaritans can be called free on 116 123, day or night. confirmedas of 2026-10-11

    10. [10]

      Find A Helpline lists free, confidential helplines verified with crisis centers in more than 175 countries. confirmedas of 2026-10-11

      • Find A Helpline · Find A Helpline (ThroughLine) · Primary source (retrieved 2026-10-11)
    11. [11]

      On 4 June 2024 the FDA's Psychopharmacologic Drugs Advisory Committee met to discuss Lykos Therapeutics' new drug application 215455 for midomafetamine (MDMA) capsules for PTSD. confirmedas of 2024-06-04

    12. [12]

      Members who voted that MDMA was effective shared the unblinding concerns but said they could not overlook the large effect sizes. confirmedas of 2024-06-04

    13. [13]

      The committee voted 10 to 1 that the benefits of MDMA with FDA's proposed risk evaluation and mitigation strategy did not outweigh its risks for PTSD, with many members saying more efficacy and safety data were needed. confirmedas of 2024-06-04

    14. [14]

      Lykos said the concerns included whether its data showed durability of effect and expectancy bias stemming mainly from participants with prior MDMA use, and maintained that its data were sufficient. confirmedas of 2024-08-09

    15. [15]

      Lykos said advisory committee panelists also questioned how much the psychotherapy component contributes to benefit and whether it is needed. confirmedas of 2024-08-09

    16. [16]

      Lykos's chief executive said another phase 3 study would take several years. confirmedas of 2024-08-09

    17. [17]

      A 2021 randomised, double-blind, placebo-controlled phase 3 trial in severe PTSD (MAPP1, Nature Medicine) reported that MDMA-assisted therapy reduced CAPS-5 symptom scores significantly more than placebo with the same therapy (effect size d = 0.91). confirmedas of 2021-05-10

    18. [18]

      A 2023 confirmatory phase 3 trial (MAPP2) randomised 104 people with moderate to severe PTSD; CAPS-5 scores fell by 23.7 points with MDMA-assisted therapy versus 14.8 with placebo and therapy (d = 0.7). confirmedas of 2023-09-14

    19. [19]

      In MAPP2, five people in the MDMA group and two in the placebo group had a severe treatment-emergent adverse event, and there were no deaths or serious adverse events. confirmedas of 2023-09-14

    20. [20]

      In August 2024 the journal Psychopharmacology retracted a 2020 pooled analysis of long-term outcomes from six phase 2 MDMA-assisted therapy trials, citing undisclosed protocol violations amounting to unethical conduct at one study site and an incompletely declared competing interest; several authors disagreed with the retraction. confirmedas of 2024-08-10

    21. [21]

      A phase 2 double-blind trial published in the NEJM in 2022 randomised 233 adults with treatment-resistant depression to a single dose of synthetic psilocybin (25 mg, 10 mg or a 1 mg control) with psychological support; it was funded by COMPASS Pathfinder. confirmedas of 2022-11-03

    22. [22]

      In that trial the 25 mg dose, but not 10 mg, reduced depression scores significantly more than 1 mg over three weeks (MADRS difference -6.6 points), but sustained response at 12 weeks was not generally supportive. confirmedas of 2022-11-03

    23. [23]

      Adverse events occurred in 77% of participants in the 2022 psilocybin trial, including headache, nausea and dizziness, and suicidal ideation or behaviour or self-injury occurred in all dose groups; the authors said larger and longer trials were needed. confirmedas of 2022-11-03

    24. [24]

      Compass reported 52-week open-label data from its COMP005 trial and 6-month data from COMP006, and said an additional dose in the open-label extension extended durability to one year; these figures are company-reported. reportedas of 2026-11-03

    25. [25]

      The FDA selected COMP360 for a Commissioner's National Priority Voucher, which entitles a company to enhanced communication and a shortened 1–2 month review after an NDA is filed; COMP360 also holds Breakthrough Therapy designation for TRD. confirmedas of 2026-08-05

    26. [26]

      On 3 November 2026 Compass Pathways said its rolling New Drug Application for COMP360 psilocybin in treatment-resistant depression was nearing completion and the final submission would be filed within two weeks. confirmedas of 2026-11-03

    27. [27]

      Compass said a late-stage PTSD trial of COMP360, designed to be registration-enabling, is under way, and that it is working with the US Department of Veterans Affairs on a trial in veterans with treatment-resistant depression, including those with PTSD. confirmedas of 2026-11-03

    28. [28]

      Executive Order 14401 directs the FDA to give National Priority Vouchers to eligible psychedelic drugs with Breakthrough Therapy designation, directs FDA and DEA to set up a Right to Try access pathway, and allocates at least $50 million to partner with states on psychedelic research. confirmedas of 2026-04-22

    29. [29]

      The order also tells the Attorney General, consulting HHS, to begin and complete a review of any Schedule I product that has successfully completed phase 3 trials for a serious mental health disorder so that rescheduling, if appropriate, can proceed. confirmedas of 2026-04-22

    30. [31]

      Compass said it expects a US launch of COMP360 in the first half of 2027, subject to FDA approval. reportedas of 2026-11-03· forecast

    31. [32]

      The Oregon Health Authority describes psilocybin services as a health and wellness option in Oregon and notes that psilocybin remains a Schedule I substance under the federal Controlled Substances Act. confirmedas of 2026-11-07

    32. [33]

      Experts at the University of Pennsylvania's Leonard Davis Institute said psychedelic-assisted therapies show promise but the evidence remains limited and larger, more rigorous trials are needed before widespread adoption. reportedas of 2026-10-11· interpretation

    33. [34]

      In Oregon, psilocybin services consist of preparation, administration and integration sessions provided by a licensed facilitator. confirmedas of 2026-11-07

    34. [35]

      Oregon's psilocybin services are open to people aged 21 or older, including non-residents, with no prescription or medical referral required, but a preparation session with a licensed facilitator must come first. confirmedas of 2026-11-07

    35. [36]

      Under Oregon law, psilocybin products can be bought only at a licensed service center during an administration session and may not be taken off-site. confirmedas of 2026-11-07

    36. [37]

      On 1 September 2026 Oregon Psilocybin Services merged with the Oregon Medical Marijuana Program to form the Oregon Health Authority's Medical Cannabis & Psilocybin (MCAP) Section. confirmedas of 2026-11-07

    37. [38]

      Colorado's Natural Medicine Division licenses natural medicine businesses including healing centers, cultivations, manufacturers and testing facilities. confirmedas of 2026-11-07

    Revision history (3)
    1. Attributed the contents of the FDA's 2024 complete response letter to Lykos, whose announcement is the only public source.
    2. Compass completed its COMP360 New Drug Application on 9 November 2026; status, FAQ and forecast updated.
    3. Page created.

    Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Dec 4, 2026.

    Cite this page

    "Psychedelic therapy: what the evidence on MDMA and psilocybin shows." ContentLora, updated Nov 14, 2026. https://contentlora.com/analysis/psychedelic-therapy-evidence-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.